In an interview with Targeted Oncology ®, Stefania Morganti, MD, PhD, research fellow at the Dana-Farber Cancer Institute, ...

Panelists reflect on clinical experience with immunotherapy combinations, the role of biomarkers, and the future of ...

MRD detection via ctDNA poses challenges in managing breast cancer patients in complete remission, especially when imaging is ...

Axi-cel demonstrated a 90% overall response rate and 75% complete response rate in relapsed/refractory indolent non-Hodgkin lymphoma. Median progression-free survival was 62.2 months, with a median ...

Minimal residual disease (MRD)—minute populations of cancer cells undetectable by conventional imaging—remains the chief ...

Circulating tumor DNA (ctDNA) revolutionizes minimal residual disease detection, offering a less invasive, real-time method ...

Ike Onwere, MD: It is [sometimes] based on giving the FOLFOX [leucovorin, fluorouracil, and oxaliplatin] every 2 weeks. It’s ...

FDA approves daratumumab for high-risk smoldering multiple myeloma, transforming treatment strategies and enhancing patient outcomes in early intervention.

Lifileucel showed a 31.4% objective response rate and a median duration of response of 36.5 months in advanced melanoma patients. The median overall survival was 13.9 months, with adverse events ...

Biomarkers such as ring sideroblasts are indicators for response to treatments like luspatercept (Reblozyl). In patients with ...

Sonrotoclax has received FDA priority review for relapsed or refractory mantle cell lymphoma, indicating potential substantial treatment improvement. The BGB-11417-201 study demonstrated significant ...

The subcutaneous formulation of toripalimab demonstrated noninferior pharmacokinetics compared to the intravenous version in ...